OBJECTIVE-Treatment of diabetic patients by pancreatic islet transplantation often requires the use of islets from two to four donors to produce insulin independence in a single recipient. Following isolation and transplantation, islets are susceptible to apoptosis, which limits their function and probably long-term islet graft survival.
RESULTS-V5 treatment upregulated expression of anti-apoptotic proteins Bcl-2 and XIAP (X-linked inhibitor of apoptosis protein) by more than 3-and 11-fold and downregulated expression of apoptosis-inducing proteins Bax, Bad, and nuclear factor-B-p65 by 10, 30, and nearly 50%, respectively. Treatment improved the recovered islet mass following collagenase digestion and isolation by 44% and in vitro glucose-responsive insulin secretion nearly fourfold. Following transplantation in streptozotocin-induced diabetic mice, 150 V5-treated islet equivalents functioned as well as 450 control untreated islet equivalents in normalizing blood glucose.
CONCLUSIONS-These studies indicate that inhibition of apo-
ptosis by V5 significantly improves islet function following isolation and improves islet graft function following transplantation. Use of this reagent in clinical islet transplantation could have a dramatic impact on the number of patients that might benefit from this therapy and could affect long-term graft survival. Diabetes 56:1259-1267, 2007 P ancreatic islet transplantation holds great promise as a treatment for type 1 diabetes. Insulin independence has been accomplished using a glucocorticoid-free immunosuppression regimen but often requires transplantation of islets from two to four donors (1) (2) (3) . Since there is a considerable shortage of pancreas donors suitable for islet isolation, relatively few diabetic patients have benefited from this form of therapy. More effective recovery of islets from donor pancreata would dramatically increase the number of patients that could be treated by islet transplantation and could improve long-term graft survival (4 -6) .
Following transplantation, islets undergo apoptosis and necrosis from transient local hypoxia, a lack of nutrient support (7, 8) , and hyperglycemia-induced toxicity (9, 10) . While use of fibroblast growth factor-2 (FGF-2) at the time of transplantation improves revascularization of islet grafts and facilitates their engraftment (11) , this approach addresses only part of the problem. Collagenase digestion of the pancreas has been shown to induce apoptosis of isolated islets from anoikis and loss of cell-matrix interactions (12, 13) . In addition, islets express proinflammatory nuclear factor-B (NF-B)-dependent genes after isolation, amplifying apoptosis signaling and potentially inducing immunological rejection (14 -16) . Optimization of the isolation process to reduce islet stress has failed to improve recovery, leaving uncontrolled apoptosis as the main cause of poor islet yield (3, 13, 17) .
Investigators have attempted to prevent ␤-cell apoptosis by transferring antiapoptosis molecules (A20, Bcl-2, the I␤ [inhibitor of ␤] repressor, and X-linked inhibitor of apoptosis protein [XIAP] ) and growth factors (hepatocyte and vascular endothelial) into islet grafts (18 -27) . In most cases, these genes have been delivered by recombinant adenovirus. This approach, however, is not without potential risk (28) . Use of IGF-II (29) , leptin (30) , and 17 ␤-estradiol (31) has improved islet mass recovery and viability but has not affected the number of islets that are needed following transplantation to correct diabetes in mice. The caspase-3 inhibitor Z-DEVD-fmk (32) improves islet recovery and viability but inhibits only caspase-3. Whereas these methods have helped reduce apoptosis during islet isolation, few methods have been developed to reduce apoptosis after islet transplantation.
We examined the efficacy of the cell-permeable pentapeptide apoptosis inhibitor V5, which inhibits a wide range of caspases, on improving pancreatic islet recovery. This molecule binds Bax and prevents mitochondrial cytochrome c translocation (33) , resulting in global inhibition of caspases through activation of NF-B-dependent and BH1-4 genes (14, 15, 22) . In this study, we demonstrate that culture of isolated islets with V5 improved islet recovery and their capacity for glucose-responsive insulin secretion. Use of FGF-2 and V5 decreased the number of islets needed to correct diabetes following transplantation threefold and allowed routine correction of glucose homeostasis in mice using islets from a single donor.
RESEARCH DESIGN AND METHODS
Peptide synthesis and preparation. Synthesis of a V5 was carried out at Sigma Genosis (Ishikari, Japan). The purity of the material was 98.8%, and the total amount of the product was 48.9 mg. Dried peptide powders were stored at Ϫ80°C and dissolved in fresh pure water for the experiments. Islet isolation and culture. Male inbred Balb/C mice, 20 g and 10 -12 weeks old, were used as pancreas donors. All the experiments performed were approved by the institutional ethical committee and were conducted according to its guidelines. Mouse islet isolation was performed with Hank's balanced salt solution (HBSS) (GibcoBRL, Grand island, NY), containing 2 mg/ml type-V collagenase (Sigma-Aldrich, St. Louis, MO), 2 mg/ml soybean trypsin inhibitor (Sigma-Aldrich), and 0.2% BSA (Sigma-Aldrich), using a modified Gotoh's method with Histopaque 1077-RPMI 1640 medium gradient (Sigma-Aldrich).
Islets were handpicked up under a microscope and cultured with RPMI-1640 (GibcoBRL) at 37°C and 5% CO 2 for in vitro analyses. Freshly isolated islets were used immediately for transplantation experiments. Islet viability was evaluated using a Live & Dead detection kit (Molecular Probes, Eugene, OR) in accordance with the manufacturer's instructions. Purity of islets was assessed by dithizone staining, and islet equivalents' yield was determined using a phase-contrast microscopy with a squared calibrated grid. One islet equivalent was equal to a spherical islet of 150 m in diameter. ATP content of islets, directly after isolation and following 24 h of culture, was measured at SRL (Tokyo, Japan) using 500 islet-equivalent aliquots per experiment in three separate studies. Measurement of mitochondrial activity of islets. Islets of 50 islet equivalents were cultured for 24 h with or without 100 mol/l V5 in each well of six-well plates (BD Biosciences, San Jose, CA), and mitochondrial dehydrogenases activity of islets were comparatively measured using 0.5 mg/ml of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) (MTT reagent; Sigma). Freshly isolated islets were used as a positive control (34) . Three independent experiments were performed. Detection of apoptosis of islets by annexin-V expression. Expression of annexin-V was measured in islets treated with or without 100 mol/l V5 at 24 h of culture. Islets were washed twice with HBSS and dispersed to a single cell by gentle pipeting in trypsin-EDTA (Sigma-Aldrich). Single islet cells were washed twice with HBSS containing 10% newborn calf serum (Sigma-Aldrich) and labeled with an annexin V-enhanced green fluorescent protein apoptosis detection kit (MBL, Nagoya, Japan), according to the manufacturer's instructions, and analyzed by a MoFlo cell sorter (Dako-Cytomation, Tokyo, Japan). Apoptotic cells were identified by the fluorescence of enhanced green fluorescent protein. Freshly isolated islets were used as a control (3) . Three independent experiments were performed. Power blot analysis for apoptosis-associated molecules. Islets (1,000 islet equivalents) were cultured with RPMI-1640-S with or without V5 (100 mol/l) for 24 h. Then, islets were washed with HBSS twice, rinsed with ice-cold lysis buffer of PBS containing 1.0% Triton X-100 (Sigma-Aldrich), sonicated for 30 s, and placed on ice for 10 min. Lysates were centrifuged at 15,000 rpm for 10 min at 4°C to exclude cellular debris. Protein concentrates were collected and analyzed for 50 apoptosis-associated molecules according to the manufacture's protocol (Clonotech, Tokyo, Japan). Three independent experiments were performed.
Measurement of insulin secretion, insulin content, and stimulation index of islets. Islets (10 islet equivalents/well of six-well plates) were cultured in RPMI-1640-S supplemented with or without V5 (100 mol/l) in both standard and ultralow attachment plates (BD Bioscience, Tokyo, Japan). Islets were treated for 20 min in 2 ml of Krebs-Ringer balanced buffer (KRBB) (containing 143.0 mmol/l Na, 5.8 mmol/l K, 2.5 mmol/l Ca, 1.2 mmol/l Mg 2 , 124.1 mmol/l Cl, 1.2 mmol/l PO-4, 1.2 mmol/l SO-4, 25 mmol/l HCO-3, 10 mmol/l HEPES, 0.2% BSA, and 3.3 or 25 mmol/l glucose) at pH 7.4 for RPMI-1640-S equilibration. Insulin secretion of the islets was measured under static incubation using a Mercodia mouse insulin enzyme-linked immunosorbent assay kit (Uppsala, Sweden) at 0, 24, 72, 120, and 168 h, as previously reported (35, 36) . Briefly, islets were first incubated at 37°C and 5% CO 2 for 2 h in KRBB with 3.3 mmol/l glucose, then in KRBB with 25 mmol/l glucose for 2 h, and finally in KRBB with 3.3 mmol/l glucose. Amount of insulin content of islets was measured at the end of static incubation. Three independent experiments were performed. Transplantation experiments. Female inbred Balb/C mice, 20 g and 10 weeks old, received a single intraperitoneal injection of 220 mg streptozotocin per kg body wt. Mice with blood glucose levels Ͼ360 mg/dl on a minimum of two consecutive measurements were selected as recipients (34) . Gelatinized microspheres for islet transplantation (30 -50 m in size) containing both FGF-2 (100 ng) and V5 (100 mol/l) or FGF-2 (100 ng) only were prepared through glutaraldehyde cross-linking of an aqueous gelatin solution, as previously reported (37) . For transplantation, freshly isolated islets were suspended in 10 l RMPI-1640-S medium, embedded with the gelatinized microspheres, and then transplanted under the kidney capsule of diabetic mice.
Diabetic mice were divided into the following four groups: 1) n ϭ 21, transplantation with 150 islet equivalents obtained from one mouse prepared with FGF-2 only; 2) n ϭ 21, transplantation with 150 islet equivalents obtained from one mouse prepared with both FGF-2 and V5; 3) n ϭ 21, transplantation with 450 islet equivalents obtained from three mice prepared with FGF-2 only; and 4) n ϭ 5, animals received no islet transplants. Normal healthy mice were used as a positive control (group 5; n ϭ 5). In vivo evaluation after islet transplantation in diabetic mice. Blood glucose levels were monitored at regular intervals for 27 weeks. Normoglycemia was defined to be Ͻ126 mg/dl in at least two consecutive measurements. An intraperitoneal glucose tolerance test was performed at 24 weeks. Mice were fasted overnight and then glucose (1g/kg body wt) was injected intraperitoneally, as previously described (34) . Nephrectomy was performed at 26 weeks in the mice of groups 1, 2, and 3, and total insulin content of the samples was measured per microgram graft (34) . Histological studies of kidneys bearing islet grafts. Kidneys bearing islet grafts were removed at 3 days and at 26 weeks after transplantation (n ϭ 3 from groups 1, 2, and 3), fixed in 10% formalin for 24 h, and embedded in paraffin for hematoxylin-eosin staining, insulin staining, and transferasemediated dUTP nick-end labeling (TUNEL) staining. Serial-matched paraffin sections were used for these stainings. Polyclonal anti-insulin guinea pig primary antibodies (Dakocytomation) were applied. Then, secondary antibody phycoethrin-labeled anti-guinea pig (Amersham Biosciences) was added. Green fluorescent nuclear counterstaining was used for all the samples. Immunofluorescent stained slides were observed under a confocal laser-scanning microscope (LSM510; Carl Zeiss) (34) . An in situ cell death detection tetramethylrhodamine red kit (Roche, Mannheim, Germany) was used for TUNEL staining. PCR analysis. For detection of inflammatory molecules, total RNA was extracted from kidneys bearing islet grafts 2 days after transplantation using RNA Trizol (Invitrogen), as previously reported (38) . RT-PCR was performed at 22°C for 10 min and then at 42°C for 20 min using 1.0 g RNA per reaction to ensure that the amount of cDNA amplified was proportional to the mRNA present in the original samples. The following specific primers were used: interleukin (IL)-1␤ (NM_008361), 5Ј-caggcaggcagtatcactca-3Ј forward and 5Ј-agctcatatgggtccgacag-3Ј reverse; tumor necrosis factor (TNF)-␣ (NM_01369), 5Ј-agtccgggcaggtctacttt-3Ј forward and 5Ј-ggtcactgtcccagcatctt-3Ј reverse; Bcl-2 (NM_009741), 5Ј-aggagcaggtgcctacaaga-3Ј forward and 5Ј-gcattttcccaccactgtct-3Ј reverse; and GAPDH (NM_008084) 5Ј-acccagaagactgtggatgg-3Ј forward and 5Ј-cacattgggggtaggaacac-3Ј reverse. Immunoelectron microscopic examination of kidneys bearing islet grafts. At 26 weeks, kidneys bearing islet grafts were harvested (n ϭ 3 each from groups 1, 2, and 3) and fixed with 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 mol/l phosphate buffer at pH 7.4. Samples were embedded in LR White (London Resin, London, U.K.). Ultrathin sections on nickel grids were incubated with 6 mol/l urea in 0.1 mol/l glycine-HCl buffer (pH 3.5) for 5 min to etch the surface of sections. The grids were incubated with polyclonal anti-insulin-guinea pig primary antibodies (DakoCytomation) at 4°C overnight. After washing, the grids were incubated for 1.5 h with 10 nm colloidal gold-conjugated goat anti-guinea pig IgG (British Biocell Interna-
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tional). The grids were washed, postfixed with 2% glutaraldehyde, rinsed with ddH2O, and dried. The sections were stained with 2% uranyl acetate for 15 min and 3% lead citrate for 1 min and observed with a Hitachi H-7100 transmission electron microscope (35) . Statistical analysis. Results were expressed as means Ϯ SE. For comparisons between two groups, the paired or unpaired Student's t test (two tailed) was used. For multiple comparisons, the one-way ANOVA was used. KaplanMeier method was used to calculate the survival data. A P value Ͻ0.05 was considered significant when determined by the Mann-Whitney U test.
RESULTS
Effect of treatment with V5 on islet viability and function, as well as parameters associated with apoptosis in vitro. Pancreatic islet yield following isolation was 152.5 Ϯ 3.46 islet equivalents per mouse. Islet viability immediately after isolation, and 12 and 24 h later in control culture, was 99.1 Ϯ 0.7%, 81.0 Ϯ 1.2%, and 72.0 Ϯ 0.9%, respectively, whereas viability at the same time points after culture in the presence of 100 mol/l V5 was 98.9 Ϯ 0.6%, 95.4 Ϯ 0.8%, and 93.5 Ϯ 0.6%. To assess the effect of V5 on islets recovered under clinically relevant donor recovery conditions, we also evaluated the effect of V5 on mouse islets isolated in association with 12 h of cold ischemia and 30 min of warm ischemia. We found that V5 was effective in protecting mouse islets under these conditions (Table 1) . Since apoptosis is often reflected in mitochondrial function, we assessed mitochondrial dehydrogenase activity 24 h after isolation. As shown in Fig. 1A , mitochondrial dehydrogenase activity was significantly greater in V5-treated islets (96.4 Ϯ 1.5%) than that in control untreated islets (54.0 Ϯ 5.7%). We also measured the expression of annexin-V, an early marker of apoptosis, 24 h after isolation. V5-treated islets expressed significantly less annexin-V (14.0%) than control untreated islets (58.5%) (Fig. 1B-D) . A power blot was then performed to identify proteins significantly (more than twofold) altered in isolated islets after treatment for 24 h in V5. Power blot analysis screened over 50 proteins associated with apoptosis (Fig. 1E) . Western blot analysis showed a 0.11-fold reduction in the expression of the pro-apoptotic protein Bax, a 0.34-fold reduction in Bad, and a 0.46-fold reduction in NF-B-p65. Treatment of islets with V5 also generated an 11.76-fold upregulation in XIAP and a 3.31-fold increase in Bcl-2 expression (Fig. 1E and F) .
To further investigate the effect of V5 on recovered islets, we analyzed glucose-responsive insulin secretion, or insulin secretion index, immediately after isolation and 24, 72, 120, and 168 h later. Since islets adherent to culture plates lose function quickly, analysis was performed on islets under both adherent and nonadherent conditions. V5-treated islets had a 2.7-to 3.7-fold higher insulin secretion index than control untreated islets at all time points under both adherent and nonadherent conditions ( Fig. 2A and B) , and V5-treated islets maintained their insulin content (128 Ϯ 1 at 24 h and 76 Ϯ 6 at 168 h under adherent culture conditions; 128 Ϯ 3 at 24 h and 101 Ϯ 5 at 168 h under nonadherent culture conditions) significantly better than untreated control islets (116 Ϯ 5 at 24 h and 9 Ϯ 2 at 168 h under adherent culture conditions; 117 Ϯ 4 at 24 h and 80 Ϯ 4 at 168 h under nonadherent culture conditions) (Fig. 2C and D) , respectively.
Effect of V5 on recovered islets after transplantation.
To investigate the effect of V5 treatment on recovered islets after transplantation, we transplanted V5-treated and control untreated islets into streptozotocin-induced diabetic mice. Transplantation procedures induce a meaningful grade of apoptosis, dramatically reducing the islet engraftment capacities and its survival by induction of the inflammatory reactions. We examined the potential prevention of apoptosis in vivo by microspheres containing V5 and FGF-2 within the islets grafts, 3 days after transplantation, by insulin staining and TUNEL assay. We found that the number of insulin-positive cells was significantly maintained by V5 treatment (150 control untreated islet equivalents: 51 Ϯ 9 cells/high power field vs. 150 V5-treated islet equivalents: 202 Ϯ 23 cells/high power field; Fig. 3A-F and J) . Notably, a significantly larger number of TUNEL-positive cells were observed in control untreated islet grafts than found in V5-treated islets (Fig. 3G-I and K). V5 treatment significantly reduced inflammatory molecule IL-1␤ and TNF-␣ gene expression and enhanced Bcl-2 gene expression in islet grafts (Fig. 3) .
In consistency with this, following transplantation of 150 V5-treated islet equivalents (recovered from one donor), normoglycemia was achieved in all diabetic recipients within 12 days and 100% 6-month survival obtained ( Fig. 4A and B) . In contrast, transplantation of 150 control untreated islet equivalents (recovered from one donor) failed to tightly control blood glucose levels, and 60% of diabetic recipients died 6 months after transplantation. Transplantation of 450 control untreated islet equivalents (recovered from three donors) corrected hyperglycemia to the same degree as transplantation of 150 V5-treated islet equivalents and produced a similar degree of blood glucose control to that after transplantation of 150 V5-treated islet equivalents following glucose challenge (Fig. 4C) . Removal of kidneys bearing islet grafts 26 weeks after transplantation produced hyperglycemia in all transplanted mice, indicating that the islet grafts were responsible for correction of diabetes. Histological analysis of V5-treated islet grafts showed a comparatively equal amount of both total insulin content (16.1 Ϯ 0.4 g/graft), compared with those (16.7 Ϯ 1.4 g/graft) of V5-untreated 450 islet equivalents (Fig. 4D) , and size of the functional islet grafts (Fig. 5B, C, E, and F) . Insulin immunoelectron microscopy 26 weeks after transplantation showed ␤-cells with numerous secretory granules and well-preserved ultrastructure organelles following V5-treatment (Fig. 5H  and J) , whereas control untreated islet grafts showed fewer ␤-cells, each containing fewer insulin secretory granules and organelles ( Fig. 5G and J) .
DISCUSSION
Type 1 diabetes results from the loss of insulin-producing pancreatic ␤-cells by ␤-cell-specific autoimmune responses. Pancreatic islet transplantation is one possible method for the cure of diabetes; however, the shortage of human donor pancreata limits the widespread application of this procedure (1, 5, 6) . Because a relatively large ␤-cell mass from two to four donor pancreata is needed to achieve normoglycemia in the recipient, it is crucial to develop treatments that would reduce loss of transplanted islets due to apoptosis and maximize use of the limited amount of donor tissue. Isolation of human islets is very stressful on the cells as it disrupts cell-cell and cell-matrix interactions and results in islet apoptosis (9, 12, 13, 17, 32, 38, 39) . Alterations in islet fine structure can be seen shortly after isolation and culture in vitro. Prevention of apoptosis has been a target to maintain islet mass for transplantation; for example, overexpression of XIAP (26) or A20 (23) in mouse islets by adenoviral vector-mediated delivery prevented early posttransplant apoptosis and reduced the islet cell mass needed to achieve normoglycemia. Although ex vivo gene transfer procedures using viral vectors are attractive, adenovirally transduced islets should be cultured to eliminate the risk of viral gene transfer to recipients. Thus, it would be beneficial to develop a simple, efficient method to protect islets from apoptosis and reduce the number of islets required for transplantation.
Bax is a member of the Bcl-2 family of proteins and plays a key role in the induction of apoptosis. In response to apoptotic stimuli, Bax translocates from the cytosol to mitochondria and causes release of apoptogenic factors (40) . Inhibition of Bax would be extremely useful in islet culture immediately after isolation procedure. Ku70 plays an important role in DNA double-strand break repair in the nucleus (41) . Ku70 binds Bax in the cytosol and inhibits its translocation into mitochondria (33) . The Bax-binding 
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domain of human Ku70 consists of residues 578 -583, and a pentapeptide (i.e.,V5) contained within these residues is cell permeable and suppressed Bax-mediated apoptotic cell death in several types of human cells, including hepatoma Hep3B cells and myeloid 32D (EpoR wt) cells (14) . We previously found that V5 treatment of monkey hepatocyte cultures improved differentiated function and prolonged cell survival (42) . In this study, we investigated the effect of V5 on islet viability and functionality during islet isolation and transplantation into diabetic mice.
First, we examined the effect of V5 on apoptosis of islets in vitro. We found that fluorescein isothyocyanate-labeled V5 (100 mol/l) was uniformly taken up by islet cells within 3 h when added into the culture, and no cytotoxic effects were observed with a dose Յ500 mol/l (data not shown). Treatment of islets isolated from Balb/c mice with V5 peptide significantly increased viability and inhibited apoptosis.
The mitochondrial metabolite, succinate, is a key metabolic mediator of glucose-stimulated preproinsulin gene transcription and translation (43) . Therefore, we examined mitochondrial function in V5-treated islets and found that mitochondrial function was increased by ϳ42% compared with untreated islets. Preservation of mitochondrial function in ␤-cells is critical for preserving their capacity to produce, store, and secrete insulin. V5 treatment significantly enhanced ATP levels in both 12-h cold preserved and 30-min warm preserved islets (Table 1 ) and markedly reduced apoptosis. Consistent with these findings, glucose-responsive insulin secretion was also increased by 2.7-to 3.7-fold in V5-treated islets. Islets treated with V5 maintained the insulin content of freshly isolated islets, even after 1 week of culture. Since islet culture seems to be an important step in the islet transplantation, the use of V5 might constitute an important tool for maintaining more viable islets with enhanced insulin secretion over the conventional cultures, floating better than adherent culture with matrices. Second, we examined the expression of proteins involved in the regulation of apoptosis in V5-treated islets. We found that the expression of pro-apoptotic molecules Bax, Bad, and NF-B was markedly reduced, and the expression of anti-apoptotic molecules XIAP and Bcl-2 was upregulated. XIAP has previously been shown to improve ␤-cell growth, survival, and metabolic function during stress (35, 44, 45) and affects Akt/protein kinase B phosphorylation (36, 45) , modulating Bad, caspase-9, Bcl-2, cyclic AMP-response element-binding 
protein, and insulin receptor substrate-1 downstream. These changes may help to protect V5-treated islets from apoptosis and increase graft survival. The beneficial effects of XIAP have been reported. Overexpression of XIAP markedly enhanced ␤-cell survival and functional recovery of islets in hypoxia-and cytokineinduced injury in vitro (27) . Overexpression of XIAP in human islets reversed the negative effects of immunosuppressive drugs on insulin secretion and cell viability (46) . Recently, it was reported that XIAP overexpression in human islets prevented posttransplant apoptosis and reduced the islet mass required to treat diabetes (26) .
These promising in vitro results suggested that V5 treatment might preserve the islet mass in grafts and thus reduce the number of islets needed to obtain insulin independence. Local hypoxia and lack of nutrients can cause apoptosis in islet transplants (8) . Early vascularization of islet grafts can overcome these problems and facilitate islet engraftment. We have previously found that use of gelatinized microspheres containing slow-release, cross-linked FGF-2 that persists for ϳ2 weeks produced rapid islet revascularization at the site of implantation (37) . In those mouse islet transplantation studies, islet graft function was improved by improved vascularization. However, we also encountered considerable transplantation-associated apoptosis that resulted in loss of islet mass (11) . Therefore, in this study, we transplanted islets embedded in microspheres containing FGF-2, to enhance vascularization, and V5, to reduce apoptosis, and found that apoptosis was decreased and the number of insulinpositive cells was increased in grafts containing islets treated with V5. When we embedded 150 islet equivalents within FGF-2-conjugated microspheres along with V5, diabetes was remitted within 12 days in streptozotocininduced diabetic mice, similar to the results seen in mice transplanted with 450 islet equivalents with FGF-2 only, suggesting that normoglycemia could be achieved with islets from a single donor if V5 is provided. Interestingly, V5 treatment significantly depressed inflammatory molecule IL-1␤ and TNF-␣ gene expression in islet grafts. We found that V5 treatment similarly affected allogenic islets following transplantation in preliminary studies (supplementary Fig. 1 [ available in an online appendix at http:// dx.doi.org/10.2337/db06-1679]). We next plan to explore methods to protect transplanted islets from autoimmune attack and early recurrence of diabetes following allogeneic islet transplantation.
In conclusion, we have shown that treatment of islets with V5 increases islet viability, enhances islet function, and prevents apoptosis. Transplantation of islets along with FGF-2 and V5 allowed a smaller islet mass (singledonor pancreas) to be used for transplantation; normoglycemia was achieved and insulin content and islet function were preserved posttransplantation. Timed release of V5, perhaps by gelatinization, may result in long-term prevention of apoptosis and improve outcomes in human islet transplantation.
